Equities research analysts expect Recro Pharma Inc (NASDAQ:REPH) to announce sales of $18.03 million for the current quarter, Zacks reports. Two analysts have provided estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $17.50 million and the highest estimate coming in at $18.55 million. Recro Pharma reported sales of $17.78 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 18th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $99.61 million for the current fiscal year, with estimates ranging from $99.10 million to $100.12 million. For the next financial year, analysts anticipate that the business will report sales of $116.02 million, with estimates ranging from $115.14 million to $116.90 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.06). The firm had revenue of $25.26 million during the quarter, compared to analyst estimates of $19.83 million.
REPH has been the subject of several analyst reports. ValuEngine cut Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. BidaskClub lowered Recro Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Stephens cut their price target on Recro Pharma from $23.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. Finally, Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $14.90.
Several institutional investors have recently made changes to their positions in REPH. Nuveen Asset Management LLC purchased a new position in shares of Recro Pharma in the 2nd quarter valued at about $3,455,000. River & Mercantile Asset Management LLP purchased a new position in shares of Recro Pharma in the 2nd quarter valued at about $2,166,000. BlackRock Inc. increased its stake in shares of Recro Pharma by 14.9% in the 2nd quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock valued at $13,142,000 after purchasing an additional 167,346 shares in the last quarter. Penn Capital Management Co. Inc. purchased a new position in shares of Recro Pharma in the 2nd quarter valued at about $1,525,000. Finally, Boston Partners purchased a new position in shares of Recro Pharma in the 3rd quarter valued at about $1,537,000. Hedge funds and other institutional investors own 59.30% of the company’s stock.
Shares of REPH stock traded down $0.50 on Monday, hitting $17.03. The company had a trading volume of 209,967 shares, compared to its average volume of 354,245. The company has a 50-day moving average price of $17.02 and a 200-day moving average price of $12.91. Recro Pharma has a twelve month low of $5.53 and a twelve month high of $19.00.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
See Also: Inverted Yield Curve
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Recro Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
